Amsurg — Merger or Acquisition (May 2014)
27 slides from Amsurg's merger presentation, May 29, 2014
Slide 1: AMSURG's Acquisition of Sheridan Healthcare Investor Presentation
Exhibit 99.2 AMSURG's Acquisition of Sheridan Healthcare Investor Presentation May 29, 2014
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation includes forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements include, but are not limited to, statements regarding AMSURG’s
Slide 3: Presenters
Presenters Chris Holden Claire Gulmi Chief Executive Officer Chief Financial Officer AMSURG AMSURG John Carlyle Robert Coward Chief Executive Officer President Sheridan Healthcare Sheridan Healthcare 2
Slide 4: Agenda
Agenda 1. Transaction Overview 2. Sheridan Overview 3. The New AMSURG
Slide 5: Agenda: Transaction Overview
Agenda 1. Transaction Overview 2. Sheridan Overview 3. The New AMSURG
Slide 6: AMSURG has agreed to acquire Sheridan Healthcare, a portfolio company of Hellman & Friedman
AMSURG has agreed to acquire Sheridan Transaction is immediately and significantly Healthcare, a portfolio company of Hellman & accretive to Adjusted EPS (2) and Adjusted Friedman, in a transaction valued at $2,350mm EPS growth rate and meaningfully – LTM 3/31/2014 Sheridan PF Adj Revenue and PF Adj
Slide 7: Key Deal Terms
Key Deal Terms Transaction $2,350mm total purchase price Consideration Funded with cash and AMSURG equity currently valued at approximately $615mm AMSURG may replace a substantial portion of equity consideration with cash by accessing the equity or equity-linked markets between signing and closing H
Slide 8: Combination Enhances Diversity, Scale And Payer Mix
Combination Enhances Diversity, Scale And Payer Mix ($ in millions) Pro Forma States 34 25 38 Facilities / Locations >240 >300 >540 Physicians ~3,500 ~1,100 ~4,600 LTM Revenue $1,080 $1,082 (2) $2,162 LTM Pro Forma Adj. EBITDA (1) $187 (2) $193 (2) $380 LTM Free Cash Flow $116 $91 $207 Government Pa
Slide 9: Investment Thesis
Investment Thesis Combines Two Best in Class Organizations in Complementary and Adjacent Markets Catalytic to Total and Organic Growth Potential Differentiated and Diversified Revenue and Growth Synergies Significantly Enhances M&A Opportunities Responsive To Key Trends In Healthcare 6
Slide 10: Agenda: Sheridan Overview
Agenda 1. Transaction Overview 2. Sheridan Overview 3. The New AMSURG
Slide 11: Sheridan Healthcare – Leader in Outsourced Physician Services
Sheridan Healthcare – Leader in Outsourced Physician Services Emergency Medicine Anesthesiology Children’s Services Radiology Services #1 and most experienced #2 provider in the US A leading provider in the A leading national provider in the US US provider to hospitals Services include: >1,500 anest
Slide 12: Sheridan Overview
Sheridan Overview Leading national provider of multi-specialty, Revenue outsourced physician services ($ in millions) Pro Forma Impact of Acquisitions $1,082 – Founded in 1962 $836 $919 $762 – Tenured management team $684 – #1 share in Anesthesiology $954 – #2 share in Children’s Services – Leader i
Slide 13: Leadership in Large and Fragmented Markets
Leadership in Large and Fragmented Markets Anesthesiology Emergency Services Radiology Children’s Services Market Size $25 billion $10 billion $14 billion $3 billion Sheridan Leadership No. 1 Market leader in Radiology and Emergency Services No. 2 Position Envision Sheridan 2% Team Health Envision E
Slide 14: Agenda: The New AMSURG
Agenda 1. Transaction Overview 2. Sheridan Overview 3. The New AMSURG
Slide 15: Track Record of Successful Evolution and Change
Track Record of Successful Evolution and Change GI / Single-Specialty Focus Diversified ASC Provider Integrating Services Addressable 2007: ~$5bn 2013: ~$15bn 2014: ~$70bn Market: Leading operator of single- Diversified into multi-specialty Natural evolution and integration of specialty ASCs (Largel
Slide 16: Market Forces Driving Differentiation
Market Forces Driving Differentiation Narrow Networks + Increasing Physician Employment Consolidation Vertical integration – particularly around the surgical episode of care PFP / Bundled Payments / Risk Better infrastructure and expertise to address trend toward physician Vertical Integration emplo
Slide 17: Combination Drives New Growth Synergies
Combination Drives New Growth Synergies New Contract Wins New Health System / ASC Joint Ventures Collaborative Vertical Integration with AMSURG ASC Portfolio 12
Slide 18: Leverage AMSURG Footprint To Accelerate New Contract Wins
Leverage AMSURG Footprint To Accelerate New Contract Wins AMSURG has built scale and presence in over 100 markets Combines a highly desired provider portfolio with a hospital based physician solution AMSURG footprint extends Sheridan’s reach into 13 new states Strategy yields a more comprehensive ho
Slide 19: Advances New Hospital / ASC Joint Venture Strategy
Advances New Hospital / ASC Joint Venture Strategy Physician Surgical Centers Outsourcing + Differentiated Engagement With Health Systems AMSURG currently in discussions with leading health Combined offering provides opportunity for robust systems in nearly half of all markets dialogue with decision
Slide 20: Clinical Integration of Anesthesia / ASC Portfolio
Clinical Integration of Anesthesia / ASC Portfolio ASC Anesthesia Market The AMSURG Portfolio • Substantial addressable outpatient • >$250mm anesthesia revenue anesthesia market associated with current AMSURG portfolio • Trend towards surgical volume migration to outpatient setting • >95% of AMSURG
Slide 21: Transaction Creates a Multi-Levered Growth Profile
Transaction Creates a Multi-Levered Growth Profile Pro Forma Revenue Growth Breakdown Pro Forma Growth Drivers Acquisitions Differentiated and Diversified Organic Growth Same Store Growth Organic New Contract Wins Addressable Market Expanded From $15bn to ~$70bn Status Quo Wall Street Pro Forma Cons
Slide 22: Robust Cash Flow Creation and Deleveraging Capability
Robust Cash Flow Creation and Deleveraging Capability Attractive Free Cash Flow Profile and Disciplined Approach to Leverage Recurring revenue and scale drive strong and predictable cash flows – Pro forma margins of 18%; limited bad debt expense Limited capital expenditures relative to other provide
Slide 23: Conclusion
Conclusion Combines Two Best in Class Organizations in Complementary and Adjacent Markets Catalytic to Total and Organic Growth Potential Differentiated and Diversified Revenue and Growth Synergies Significantly Enhances M&A Opportunities Responsive To Key Trends In Healthcare 18
Slide 24: Q&A
Q&A
Slide 25: Appendix
Appendix
Slide 26: Reconciliation of Non-GAAP Measures
Reconciliation of Non-GAAP Measures ($ in millions) Revenue Reconciliation Free Cash Flow Last Twelve Months Last Twelve Months as of March 31, 2014 Year Ended December 31, 2011 as of March 31, 2014 Sheridan AMSURG Sheridan Combined AMSURG Sheridan Combined Revenues $954 Operating cash flow $243 $82
Slide 27: Reconciliation of Non-GAAP Measures (cont'd)
Reconciliation of Non-GAAP Measures (cont’d) ($ in millions) EBITDA Last Twelve Months as of March 31, 2014 AMSURG Sheridan Total Net Income $72 $13 $85 Interest 29 55 84 Taxes 50 18 68 Depreciation and amortization 33 37 70 EBITDA $184 $123 $307 Proforma EBITDA of acquisitions 5 38 43 Restructuring